WithdrawnPhase 1

Pulmozyme for Sjogren's Associated Cough

Stopped: No patients enrolled.

United States0Started 2011-05

Plain-language summary

Patients with Sjogren's disease have destruction of the mucus secreting cells in the airway. This manifestation of the disease leads to the common complaint of persistent dry cough that is seen in many of these patients. This study is aimed at determining whether the regular use of Pulmozyme will result in decreased cough and improved quality of life.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years or above with primary Sjogren's disease (as defined by the American European Consensus Group Criteria), and complaint of chronic cough. * Able to give consent and anticipated ability to adhere to the study procedures. Exclusion Criteria: * Diagnosis of COPD, emphysema, asthma, chronic bronchitis, other clinically significant lung disease that is likely to cause cough. Interstitial lung disease associated with Sjogren's is not excluded. * Cigarette use of greater than 20 pack years or regular use within 6 months * Allergy or intolerance to Pulmozyme. * Acute respiratory infection or other acute respiratory illness during the prior month. * LCQ greater than 17 and VAS less than 3 cm at baseline (Visit 1). * Pregnancy or breast feeding.

What they're measuring

Changes in Leicester Cough Questionnaire (LCQ) score and cough visual analog scale.

Timeframe: After 2 weeks of therapy.

Trial details

NCT IDNCT01357447

SponsorUConn Health

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-03

View on ClinicalTrials.gov More Sjogren's Syndrome trials